GLP-1 accessibility and achieving lasting, meaningful clinical outcomes are major challenges for the healthcare ecosystem. In a new blog, Dr. Vindell Washington breaks down how the clinical implications are considered in the design of Verily Lightpath* — our personalized, AI-powered chronic-care solution — to directly address these challenges.
Exciting to see Verily Sightline, our public health monitoring solution, featured on NBC Bay Area! Data from San Francisco and San Jose wastewater plants reveal that Influenza A is declining, but Influenza B has spiked, highlighting the power of real-time public health insights. According to Verily’s Amy Lockwood, the innovation allows us to track pathogens efficiently, moving beyond traditional methods that rely on individual doctor visits.
We invite you to meet Verily experts at one of our upcoming events to hear how we’re making healthcare more personal and precise. 📍 Boston, MA - Bio-IT World Conference, April 2-4 📍 New York, NY - The Conference Board Employee Health Care Conference, April 8-9 📍 Nashville, TN - Business Group on Health 2025 Annual Conference, April 22-24 📍 New Orleans, LA - ACRP - Association of Clinical Research Professionals 2025, April 24-27 📍 Anaheim, CA - NACCHO 2025 Preparedness Summit, April 29 - May 2 Subscribe to our newsletter to stay in the know about where to find us next and the latest Verily news.
Our chronic care app includes access to a team of dedicated health coaches who help members with diabetes thrive. Marti Fernandes is one of them. Get to know why she’s so passionate about what she does.
Discover a better way to manage clinical trial protocols. Digital protocols—powered by Verily’s proprietary, AI-driven technology—enable more seamless and cost-effective clinical trial operations.
“Dr. Singh has changed my life. There are not enough adjectives to describe her, or the care that she provides me. She listens to me. She takes time to understand what is going on with me.” - Vince, Verily Onduo member Learn how Dr. Neeli Singh, endocrinologist and Medical Director of Onduo P.C., helps deliver the promise of more personal, precise diabetes care.
Verily Lead Behavioral Scientist Tomas Garcia specializes in the study of behavioral sciences – understanding how and why we make decisions, which is crucial to designing interventions that work. He shared with Infobae how Verily is combining tech and behavioral sciences to solve complex health problems: “Without understanding biases and context, there is no sustainable change. We are developing Verily Lightpath, a smart chronic care solution to help people manage their health. It is designed to be a proactive platform, which continuously integrates data and uses artificial intelligence.” “The app's modules and pathways are dynamic and use artificial intelligence to help members change behavior through rapid feedback loops. This means that the same platform can help them overcome behavioral barriers.”
AI-powered protocol digitization streamlines clinical trial operations with faster study startup timelines and improved accuracy. Read our latest blog to learn how Verily Viewpoint Digital Protocols can help bring life-changing therapies to patients faster and more efficiently.
Seasonal flu and respiratory virus rates have been severe this season, but wastewater surveillance data shows a decrease across the country. Amy Lockwood, Verily Public Health Partnerships Lead, talked to Mireya Garcia of FOX 13 Seattle about national and regional trends, what’s driving the high rates of flu, and how we can protect ourselves.
If you have plans to go to Las Vegas, insights from wastewater monitoring can help assess the public health risk of visiting high-traffic areas like bars and nightclubs. Researchers Casey Barber, Ching-Lan Chang, Michael A. Moshi, Shahraiz Akbar, Van Vo, Edwin Oh, and Daniel Gerrity used data from Verily in a new study that explored traveler- and tourism-focused wastewater surveillance in the area, showing the potential to operationalize the process on a broader scale. Read research methods and results published in Elsevier’s ScienceDirect.
